Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
avelumab + lutetium-177 dotatate
- Development stage
- Phase 2
- Lead developer
- Melanoma and Skin Cancer Trials Limited
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals, Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Administration
- Intravenous
01
Overview
This drug refers to a combination therapy consisting of the PD-L1 inhibitor **avelumab** and the radiopharmaceutical **lutetium-177 dotatate** (177Lu-DOTATATE). It is being investigated for the treatment of metastatic Merkel cell carcinoma (mMCC) in the GoTHAM clinical trial (NCT04261855). Lutetium-177 dotatate is a peptide receptor radionuclide therapy (PRRT) that targets somatostatin receptors (SSTR), particularly SSTR2, which are highly expressed on the surface of Merkel cell carcinoma cells. Once bound, it delivers targeted beta-radiation to induce DNA damage and cell death. Avelumab is a human anti-PD-L1 monoclonal antibody that prevents the interaction between PD-L1 on tumor cells and PD-1 on T-cells, thereby restoring the immune system's ability to recognize and attack the cancer. The combination aims to leverage the potential synergistic effects of radiation-induced immunogenic cell death and checkpoint inhibition.
- Other names
- 177Lu-DOTATATElutetium Lu 177 dotatateavelumabPRRTPeptide Receptor Radionuclide Therapy
02
Targets
CD274 (Programmed cell death protein 1 ligand 1)SSTR4 (Somatostatin receptor 4)SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on avelumab + lutetium-177 dotatate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on avelumab + lutetium-177 dotatate.